Physician profile
Taylor Jacobs
NPI 1720662281
$1,852.80
in general payments reported to CMS, 2019-2025
22 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $432 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.72 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $236.49 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $198.48 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $126.54 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.92 | 2024-2025 | Caplyta |
| Edwards Lifesciences Corporation | $106.69 | 2024-2025 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $103.51 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $93.95 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.11 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $67.35 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.95 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $63.32 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $47.79 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $37.65 | 2025 | Capvaxive, Gardasil 9 |
| Insulet Corporation | $37.45 | 2025 | Omnipod |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.78 | 2024 | Watchman Flx |
| Mannkind Corporation | $27.32 | 2025 | |
| Seqirus USA INC | $25.40 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $20.99 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.88 | 2025 | Breztri |
| Phathom Pharmaceuticals, INC. | $15.37 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.